Second-line treatment of small-cell lung cancer

@article{MacCallum2006SecondlineTO,
  title={Second-line treatment of small-cell lung cancer},
  author={Cecilia Mermel MacCallum and Heidi H. Gillenwater},
  journal={Current Oncology Reports},
  year={2006},
  volume={8},
  pages={258-264}
}
Approximately 45,000 new cases of small-cell lung cancer were diagnosed in 2005 in the United States. Although response to first-time therapy is up to 90%, the majority of patients will ultimately relapse. Therefore, active second-line therapy is needed for this patient population. The only second-line treatment for small-cell lung cancer approved by the US Food and Drug Administration is topotecan. Other agents have been investigated and have shown modest efficacy. These include vinorelbine… Expand
Topotecan in the treatment of relapsed small cell lung cancer
  • E. Quoix
  • Medicine
  • OncoTargets and therapy
  • 2008
TLDR
Oral topotecan is of similar efficacy and much more convenient with limited stay in a treatment unit and has a comparable toxicity profile for these patients with short expected survival, especially those who are refractory because of their short survival expectation. Expand
The Role of Immunotherapy in Extensive Stage Small-Cell Lung Cancer: A Review of the Literature
TLDR
Evidence show a statistically significant survival benefit of adding atezolizumab, an IgG1 monoclonal antibody targeting against PD-L1, to platinum-based chemotherapy plus etoposide in patients who have not received any previous systemic therapy. Expand
[Small cell lung cancer--state of the art and future perspectives].
TLDR
Topotecan now offers an effective and well tolerated monosubstance for second line therapy of recurrent SCLC, and there has been a significant increase in median survival. Expand
Therapy of small cell lung cancer with emphasis on oral topotecan.
TLDR
Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy, and is considered as the standard second-line chemotherapy in patients with small cell lung cancer. Expand
Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.
TLDR
Picoplatin demonstrated clinical efficacy in platinum-refractory SCLC and the major toxicity was hematologic, warrants further evaluation in this patient population. Expand
Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
TLDR
The absence of antitumor activity found here precludes further studies of this plitidepsin schedule as second-line single-agent treatment of SCLC. Expand
Small-cell lung cancer: an unusual therapeutic approach with more than 10-year overall survival. Case report and review of the literature.
TLDR
A case report of a patient with limited-stage small-cell lung cancer who underwent a thoracotomy for diagnostic purposes, with the diagnosis being made after surgical excision, makes this case presentation a very interesting one. Expand
Small-Cell Lung Cancer: An Unusual Therapeutic Approach with More than 10-year Overall Survival. Case Report and Review of the Literature
Small-cell lung cancer is the most aggressive lung cancer, with a dismal prognosis. The authors present a case report of a patient with limited-stage small-cell lung cancer who underwent aExpand
A NOVEL EXPLORING APPROACH OF CANCER CHEMOTHERAPY BY MULTIPLE EMULSION SYSTEM
TLDR
Whatever drug delivery technology that can reduce the total number of injection throughout the drug therapy period will be truly advantageous not only in term of compliance but also for potential to improve the quality of the therapy. Expand
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
TLDR
Patients administered second-line chemotherapy had significantly longer survival than patients administered best supportive care, however, this difference can be explained by more negative prognostic factors in the best supported care group. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 33 REFERENCES
Treatment of relapsed small-cell lung cancer--a focus on the evolving role of topotecan.
TLDR
The clinical utility of topotecan in recurrent SCLC is reviewed, including its efficacy, tolerability, and quality-of-life effect, when used as monotherapy and in novel combination regimens. Expand
Chemotherapy of small cell lung cancer: state of the art
TLDR
An update of data recently published from phase 2 and phase 3 trials is presented, showing that platinum and etoposide combination chemotherapy remains the standard of care in small cell lung cancer. Expand
Options for first- and second-line therapy in small cell lung cancer--a workshop discussion.
TLDR
In a case study-based workshop, physicians were asked to discuss various aspects of patient management in small cell lung cancer, most investigators recommended treatment with etoposide/cisplatin, with possible dosing variations according to tolerability and convenience. Expand
Emerging role of weekly topotecan in recurrent small cell lung cancer.
Small cell lung cancer (SCLC) is an aggressive tumor that often metastasizes before the primary cancer is diagnosed. Patients with SCLC are typically elderly and often have comorbidities that mayExpand
Topotecan in the treatment of relapsed small cell lung cancer patients with poor performance status
TLDR
Treatment with topotecan is feasible and well tolerated in patients with relapsed SCLC with suboptimal PS scores and provided similar benefits, including antitumor response rates and symptom palliation, in PS 0/1 and PS 2 patients. Expand
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer.
TLDR
Paclitaxel is active in drug-resistant SCLC; further investigation in combination with other active agents in this poor prognosis group is appropriate. Expand
Second-line chemotherapy in small cell lung cancer in a modified administration of topotecan combined with paclitaxel: a phase II study
TLDR
Topotecan combined with paclitaxel, given on day 1 on a weekly basis, produced a response rate of 26.83% in pretreated patients with SCLC, and myelotoxicity, particularly neutropenia, was the main adverse reaction, but in a minority of patients. Expand
Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597.
TLDR
Gemcitabine has modest activity in previously treated SCLC patients, and the favorable toxicity profile warrants further investigation, either in combination chemotherapy regimens or with targeted biologic compounds. Expand
Phase II study of imatinib in patients with small cell lung cancer.
TLDR
There was no observed antitumor activity in this limited Phase II trial of patients with SCLC, of which only a few tumors showed expression of the imatinib target. Expand
Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients
TLDR
Results suggest acceptable toxicity and some antitumour activity of vinorelbine in pretreated SCLC patients. Expand
...
1
2
3
4
...